74PD - When is a pathological diagnosis preferred before stereotactic ablative radiotherapy (SABR) for stage I lung cancer? A decision analysis

Date 27 March 2014
Event ELCC 2014
Session Poster Discussion 1
Topics Non-Small-Cell Lung Cancer, Early Stage
Pathology/Molecular Biology
Surgery and/or Radiotherapy of Cancer
Presenter Alexander Louie
Citation Journal of Thoracic Oncology (2014) 9 (Supplement 9): S7-S52. 10.1097/JTO.0000000000000131
Authors A.V. Louie1, M.G. Hunink2, P. Patel3, B.S. Ferket2, F.J. Lagerwaard1, G.B. Rodrigues4, J.K. Salama3, C. Kelsey3, D.A. Palma4, S. Senan5
  • 1Radiation Oncology, VU University Medical Center, 1007 MB - Amsterdam/NL
  • 2Department Of Epidemiology, Center for Health Decision Sciences, Harvard School of Public Health, Boston/US
  • 3Radiation Oncology, Duke University, Durham/US
  • 4Radiation Oncology, London Regional Cancer Program, London/CA
  • 5Radiation Oncology, Vrije University Medical Centre (VUMC), 1081 HV - Amsterdam/NL



In unfit patients who are at increased risk for complications from a biopsy, SABR for a solitary pulmonary nodule (SPN) is acceptable after review by a multidisciplinary tumor board [ESMO recommendations 2013]. We performed a decision analysis that can be employed to inform the appropriate lung cancer prevalence threshold of when this strategy is warranted.